Cargando…
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotec...
Autores principales: | Abdulrahman, Nabeel, Ibrahim, Meram, Joseph, Jensa Mariam, Elkoubatry, Hanan Mahmoud, Al-Shamasi, Al-Anood, Rayan, Menatallah, Gadeau, Alain Pierre, Ahmed, Rashid, Eldassouki, Hussein, Hasan, Anwarul, Mraiche, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068664/ https://www.ncbi.nlm.nih.gov/pubmed/35334035 http://dx.doi.org/10.1007/s11010-022-04411-6 |
Ejemplares similares
-
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
por: Al-Shamasi, Al-Anood, et al.
Publicado: (2021) -
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study
por: Moustafa, Diala Alhaj, et al.
Publicado: (2022) -
Asterarcys quadricellulare (Chlorophyceae) protects H9c2 cardiomyoblasts from H(2)O(2)-induced oxidative stress
por: Saadaoui, Imen, et al.
Publicado: (2022) -
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023) -
Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)